Accrued Liabilities - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.1 PLN -1.64% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ryvu Therapeutics SA
Accrued Liabilities Peer Comparison

Comparables:
I
IGN
M
MDB
S
SLV

Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Accrued Liabilities
zł9.1m
CAGR 3-Years
36%
CAGR 5-Years
15%
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Accrued Liabilities
zł85k
CAGR 3-Years
-65%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Medicofarma Biotech SA
WSE:MDB
Accrued Liabilities
zł1.3m
CAGR 3-Years
215%
CAGR 5-Years
73%
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Accrued Liabilities
zł9m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Ryvu Therapeutics SA's Accrued Liabilities?
Accrued Liabilities
9.1m PLN

Based on the financial report for Mar 31, 2024, Ryvu Therapeutics SA's Accrued Liabilities amounts to 9.1m PLN.

What is Ryvu Therapeutics SA's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
15%

Over the last year, the Accrued Liabilities growth was 40%. The average annual Accrued Liabilities growth rates for Ryvu Therapeutics SA have been 36% over the past three years , 15% over the past five years .

Back to Top